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Tocotrienol-rich fraction (TRF) is a mixture of vitamin E analogs derived from palm oil. 
We previously demonstrated that supplementation with TRF improved cognitive function 
and modulated amyloid pathology in AβPP/PS1 mice brains. The current study was 
designed to examine proteomic profiles underlying the therapeutic effect of TRF in the 
brain. Proteomic analyses were performed on samples of hippocampus, medial prefrontal 
cortex (mPFC), and striatum using liquid chromatography coupled to Q Exactive HF 
Orbitrap mass spectrometry. From these analyses, we profiled a total of 5847 proteins of 
which 155 proteins were differentially expressed between AβPP/PS1 and wild-type mice. 
TRF supplementation of these mice altered the expression of 255 proteins in the 
hippocampus, mPFC, and striatum. TRF also negatively modulated the expression of 
amyloid beta A4 protein and receptor-type tyrosine-protein phosphatase alpha protein in 
the hippocampus. The expression of proteins in metabolic pathways, oxidative 
phosphorylation, and those involved in Alzheimer’s disease were altered in the brains of 
AβPP/PS1 mice that received TRF supplementation. 





Alzheimer’s disease (AD) is the most common form of dementia, which is 
characterized by a progressive decline in memory and cognitive capabilities, 
accompanied by neuropathological hallmarks, such as aggregates of amyloid beta (Aβ) 
in plaques and neurofibrillary tangles [1]. Aβ is generated from sequential proteolytic 
processing of amyloid precursor protein (APP) by β- and γ-secretases [2]. The 
progression of AD can be influenced by genetic, environment, and lifestyle factors [3]. 
AD commonly occurs with advanced age, but it may also have an early-onset, as observed 
with familial AD through the enhanced generation and accumulation of Aβ caused by 
mutations in APP or presenilins-1 and 2 (PSEN1 and PSEN2) [4,5]. Overall, it is 
important to find a cure for AD at an early preclinical stage, and various natural-source 
compounds are one possible therapeutic approach. 
Vitamin E, a lipid soluble vitamin, has been shown to preserve cognitive function 
and general well-being in the elderly [6–8]. However, a previous randomized controlled 
trial has reported that vitamin E in the form of α-tocopherol showed no significant effects 
on AD progression compared to the placebo group [9], while, Dysken et al. showed that 
α-tocopherol was effective in slowing the progression of mild to moderate AD [6]. 
Vitamin E in the form of tocotrienols exhibits a significantly greater neuroprotective 
effect than α-tocopherol as it has been shown to protect against glutamate-induced 
neuronal death by suppressing inducible pp60 c-Src kinase activation at a nanomolar 
concentration [10]. Vitamin E is composed of tocopherols and tocotrienols. Tocopherols 
and tocotrienols have isomers, designated as α-, β-, γ-, and δ-, which differ by the number 
and position of methyl groups on the chromanol ring [11]. Tocotrienols differ from 
tocopherols by the presence of three double bonds in their isoprenoid side chain, which 
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contributes to easier penetration into saturated fatty acid layers around the brain, thereby 
providing higher efficacy and potency as antioxidants [12,13]. The combination of 
tocotrienols and tocopherols has been shown to be neuroprotective and to reduce AD risk 
at an advanced age [14]. 
A major source of vitamin E containing nearly 70% tocotrienols and 30% 
tocopherols is palm oil from Elais guineensis (African oil palm tree) [15,16]. Tocotrienol-
rich fraction (TRF), a mixture of vitamin E analogs derived from palm oil, has garnered 
attention recently. Several reports have shown the potential of TRF in modulating Aβ 
metabolism [17], brain metabolites [18,19], antioxidant defense mechanisms [19,20], and 
cancer prevention [21]. Previously we have demonstrated that long-term supplementation 
(ten months) of TRF on APPswe/PS1dE9 double transgenic (Tg) mice (AβPP/PS1), a 
mouse model of AD, reduced amyloid pathology in the brain [17]. Long-term 
supplementation of TRF has also been shown to enhance spatial memory, working 
memory, and locomotor activity of AβPP/PS1 mice [18]. Our recent metabolomics study 
showed that TRF exerts its neuroprotective effect in the AβPP/PS1 mice brain possibly 
by modulating metabolic pathways involved in bioenergetics, neurotransmission, 
membrane lipid metabolism, and oxidative stress defense [18]. However, the effect of 
TRF on AβPP/PS1 mice has not yet been investigated at the proteome level. This is 
essential to further understand the progression of AD-like pathogenesis in AβPP/PS1 
mice, and how TRF might be altering the onset and progression of the disease. 
Hence, the present study examined the proteome profile of AβPP/PS1 mice 
hippocampus, medial prefrontal cortex (mPFC), and striatum, compared to wild-type 
mice. In addition, we also analyzed the effect of TRF supplementation on these brain 
regions of AβPP/PS1 mice, by comparing them with its vehicle control group, Tg-PO 
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mice, which received palm oil stripped of vitamin E. To our knowledge, this is the first 
study analyzing the effect of TRF on untargeted proteome profile of AβPP/PS1 mice brain 
regions (hippocampus, mPFC, and striatum) by using ultrahigh-performance liquid 
chromatography (UHPLC) coupled to Q Exactive HF Orbitrap mass spectrometry. 
 
MATERIALS AND METHODS 
Animals 
APPswe/PS1dE9 double transgenic (Tg) mice (AβPP/PS1) line 85, expressing a 
chimeric mouse/human amyloid precursor protein (Mo/HuAPP695swe) and a mutant 
human presenilin 1 with deletion at exon-9 (PS1-dE9), were obtained from Jackson 
Laboratory (Bar Harbor, ME, USA) [22]. Mice were maintained by breeding 
heterozygous females with wild-type (WT) males. The offspring were genotyped by 
polymerase chain reaction (PCR) using the APP primers: 
 forward-GACTGACCACTCGACCAGGTTCTG 
/reverse- CTTGTAAGTTGGATTCTCATATCCG,  
and the following two presenilins 1 sequences: 
forward-CTCTTTGTGACTATGTGGACTGATGTCGG 
/reverse- GTGGATAACCCCTCCCCCAGCCTAGACC  
and forward- ATTAGAGAACGGCAGGAGCA 
/reverse-GCCATGAGGGCACTAATCAT.  
Only heterozygous and WT male mice were used in this study. All mice were 
housed in a controlled environment (23°C, 12-h/12-h light/dark cycle (lights on from 
8:00-20:00)) with ad libitum access to food and water. All animal protocols were 
approved by the Animal Care and Use Committee of the Shiga University of Medical 
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Science (Ethical committee approval number: 2013-6-12H). 
 
TRF supplementation 
The TRF used in this study (Sime Darby, Selangor, Malaysia) consisted of a 
mixture of α-tocopherol (168.0 mg/g), α-tocotrienol (196.0 mg/g), β-tocotrienol (24.0 
mg/g), γ-tocotrienol (255.0 mg/g), and δ-tocotrienol (75.0 mg/g). Palm oil stripped of 
vitamin E (PO) was purchased from the Malaysian Palm Oil Board (Selangor, Malaysia). 
TRF was dissolved at 12 mg/mL in PO as previously described [17].  Five-month-old 
mice were divided into four groups (n = 3 per group): two groups received water (WT-
ctrl and Tg-ctrl, 5 mL/kg body weight), one group received PO as a vehicle (Tg-PO, 5 
mL/kg body weight), and the other received TRF (60 mg/kg body weight). All mice 
received daily supplementation of TRF (Tg-TRF), PO (Tg-PO), or water (Tg-ctrl and 
WT-ctrl) by oral gavage for a duration of 10 months. The mice used in the study were 
subjected to behavioral tests (open field, novel object recognition, and Morris water 
maze) as reported in our previous study [18]. 
 
Proteome analysis in mice brain 
Brain tissue preparation 
The mice were sacrificed by cervical dislocation. Each brain was rapidly removed 
and rinsed in ice-cold 10 mM phosphate buffered saline. The brain was sectioned into 1.0 
mm coronal slices using a Mouse Brain Slicer Matrix (Zivic Instruments Inc., Pittsburgh, 
PA, USA), and further dissected into three different regions- hippocampus, medial 
prefrontal cortex (mPFC) and striatum on an ice-cold plate. Each sample was transferred 





Protein extraction, protein separation, and in-gel digestion 
Protein extraction, protein separation, and in-gel digestion were conducted 
according to our previously described method [23]. For the protein extraction procedure, 
the mice hippocampus, mPFC, and striatum were homogenized using an ultrasonicator 
(QSonica, Newtown, CT, USA). Next, the brain homogenates were centrifuged (20,600 
x g, 4 ºC, 15 min) and the supernatants were collected. Thiourea rehydration buffer was 
added to the remaining pellets. The mixture was centrifuged (20,600 x g, 4 ºC, 15 min). 
The resulting supernatants were then pooled with the earlier collected supernatants. The 
protein concentration in each sample was quantified using a Bio-Rad Bradford protein 
assay kit (Bio-Rad, California, USA). Each sample containing 50 µg of extracted protein 
was separated by gel electrophoresis at 120 V constant current. The gel was stained with 
Simply Blue Safe Stain (Invitrogen, USA) and washed thoroughly to remove excess stain. 
For in-gel digestion procedure, the gel was cut into six fractions, and further sliced into 1 
to 2 mm pieces. Next, the gel pieces were transferred into a tube containing 50% 
acetonitrile/50 mM ammonium bicarbonate solution and shaken for 15 min. The solution 
was removed and the process was repeated until no visible stain was observed in the gel 
pieces. The gel pieces were reduced with 10 mM dithiothreitol/100 mM ammonium 
bicarbonate solution, alkylated with 55 mM iodoacetamide/100 mM ammonium 
bicarbonate solution, dehydrated with acetonitrile solution, and dried in a vacuum 
concentrator. The gel pieces were then incubated overnight with 6 ng of trypsin/50 mM 
ammonium bicarbonate solution at 37 ºC. After overnight digestion, the gel pieces were 
agitated constantly for 15 min in acetonitrile solution. The solution was then transferred 
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into a new tube. The gel pieces were extracted again with 50% acetonitrile/50 mM 
ammonium bicarbonate solution. The solutions collected from both tubes were pooled 
into one tube and then dried for about 3 hours using a vacuum concentrator at 30 ºC. The 
dried peptides from each tissue sample were reconstituted in 0.1% formic acid solution 
before analysis on the liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
system. 
 
Liquid chromatography and MS/MS analysis 
Proteomics analysis was carried out using LC-MS/MS according to the methods 
described previously [23]. Upon injection of 6 µL of 50 μg extracted sample into the LC-
MS/MS system, the sample underwent chromatographic separation in the Dionex 
Ultimate 3000 UHPLC instrument (Thermo Fisher Scientific, Waltham, MA, USA) 
through reversed phase PepMap-C18 pre-column with 300 μm inner diameter x 5 mm 
length, packed with 5 µm particles, and chromatographed on a PepMap RSLC C18 2 μm, 
100 Å, 75 μm x 25 cm column (Thermo Fisher Scientific), at 35 °C. The sample was 
separated using a binary gradient mobile phase system with a total running time of 135 
min and a constant flow of 300 nL/min as described previously [23]. A Q Exactive HF 
(Thermo Scientific) quadrupole-Orbitrap hybrid instrument was used to acquire mass 
spectra and tandem mass spectra under the control of the manufacturer’s XCalibur version 
4.0 software. Electrospray ionization was set at positive mode whereas capillary 
temperature and spray voltage were applied at 275 °C and 1.6 kV, respectively. Full-scan 
mass spectra were acquired from m/z 350 to 1800 with resolution, automatic gain control 
(AGC) threshold and maximum injection time set to 120000, 3 x 106 and 100 ms, 
respectively. For data dependent acquisition, the following settings were applied. Only 
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precursors with an assigned monoisotopic m/z and a charge state of 2 to 7 were included 
for the MS/MS scans. From survey scans, the software chose in real time maximum 20 
precursor ions based on intensity and assigned charge state to trigger subsequent MS/MS 
acquisitions. Maximum injection time was set at 65 ms and isolation window of 0.7 m/z. 
Higher energy collisional dissociation (HCD) with a normalized collision energy (NCE) 
was set to 28 %. Minimum AGC threshold was set at 5 x 103, intensity threshold was kept 
at 7.7 x 104 and apex-triggered MS/MS scan was set at 2 to 15 s. Dynamic exclusion 
duration used was 20 s to avoid repeating MS/MS scan for the same precursor ion. 
 
Data analysis 
Protein identification and quantification 
The mass spectra data were analyzed by using MaxQuant version 1.5.3.30 
(http://www.maxquant.org) using a similar setting as described previously [23]. The data 
were searched by the built-in Andromeda search engine [24,25] against Mus musculus 
sequences obtained from the UniProt database (http://www.uniprot.org) accessed on 
September 2016. Protein identification was filtered using a target-decoy approach with a 
false discovery rate (FDR) of 1%. Trypsin was set as the digestive enzyme, while missed 
cleavage by the enzymatic digestion was set at two sites for the protein sequence. 
Methionine oxidation and protein N-terminal acetylation were selected as the variable 
modifications, while cysteine carbamidomethylation was chosen as the constant 
modification. Minimum peptide length and maximum peptide mass were set to seven 
amino acid residues and 4,600 Da, respectively (to avoid matching too short and too long 
tryptic peptides to protein sequences). Label-free quantification (LFQ) approach was 
applied to quantify the protein. The mass spectrometry proteomics data have been 
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deposited to the ProteomeXchange Consortium via the PRIDE [26] partner repository 
with the dataset identifier PXD011068. 
 
Bioinformatics and statistical analysis 
The data acquired from the MaxQuant was further processed using Perseus 
software (version 1.5.4.1, Max Planck Institute of Biochemistry, Martinsried, Germany) 
[27]. The analysis was carried out according to our previously described method with 
some modifications [23]. First, the data were uploaded into the Perseus software, 
followed by screening of the proteins by removing potential contaminants, identification 
of protein based on sites only, and identifications from reversed sequences. The protein 
abundances from LFQ quantifications were log-transformed.   If the calculated values 
were presented as “NaN” (Non-Assigned Number) values, the values were considered as 
missing values. The log-transformed LFQ intensity values of the proteins were filtered 
based on the minimum number of valid values in one experimental group. In the present 
study, the minimum number of valid values was set at 2, which accepted the proteins 
showing at least two valid values out of three samples in at least one experimental group 
out of four experimental groups (either Tg-ctrl, WT-ctrl, Tg-TRF, or Tg-PO groups) to 
be considered for the analysis. The missing values imputation was applied by considering 
the estimated intensity distribution. Multi-scatter plot and principal component analysis 
were carried out in order to estimate the variabilities between biological replicates of the 
brain sample. 
To identify the proteins altered in AβPP/PS1 mice, the Tg-ctrl group was 
compared to the WT-ctrl group using a two-tailed, t-test. Similarly, a t-test was also used 
to test the effect of TRF supplementation on AβPP/PS1 mice by comparing Tg-TRF with 
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its vehicle control group, Tg-PO. A protein was considered to be differentially expressed 
when the difference between groups had a p-value of less than 0.05 (p < 0.05). Benjamini-
Hochberg test was used for the FDR correction method at a cut off value 0.05. However, 
since a mild change in the expression of the proteins was observed after performing a 
Benjamini-Hochberg test, we considered the proteins with p < 0.05 as significantly altered 
in this study. Both p-value and q-value of each protein are listed in the Supplementary 
Tables 1 - 4.  
Next, in order to identify overlapped proteins between the differentially expressed 
proteins (p < 0.05) in Tg-ctrl versus WT-ctrl groups and Tg-TRF versus Tg-PO groups, 
we constructed Venn diagrams online at 
http://bioinfogp.cnb.csic.es/tools/venny/index.html [28]. Each significantly altered 
protein (p < 0.05) was subjected to pathway search against Kyoto Encyclopedia of Genes 
and Genomes (KEGG) databases (http://www.genome.jp/kegg/pathway.html) using a 
pathway enrichment tool, KEGG orthology-based annotation system (KOBAS) version 
3.0 (http://kobas.cbi.pku.edu.cn/) [29,30]. We selected Mus musculus library and KEGG 
database for the pathway search. The hypergeometric test and Fisher’s exact test were 
used for statistical testing in the pathway enrichment analysis and Benjamini-Hochberg 
was used for the FDR correction method. For each KEGG pathway, a p-value was 
calculated using a hypergeometric test, and a cutoff of 0.05 was applied to identify 
enriched KEGG pathways. Only the top five pathways with p-values less than 0.05 are 
listed in Table 2 and Table 3.  
 
RESULTS 
Profiling of differentially expressed proteins in AβPP/PS1 mice brain 
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We conducted a bioinformatic analysis of the LC-MS/MS data using MaxQuant 
and Perseus software to investigate alterations in the proteome profile of AβPP/PS1 mice 
brain supplemented with TRF extracted from palm oil. From these analyses, we identified 
5847 proteins in the hippocampus, mPFC, and striatum of the AβPP/PS1 mice control 
and wild type mice groups (Supplementary Table 1). Meanwhile, 6047 proteins were 
identified in the AβPP/PS1 mice in the TRF and PO groups (Supplementary Table 2). 
Next, we assessed the proteome data quality by comparing the relative protein 
quantification among the three biological replicates of each group. Multi-scatter plots 
with Pearson’s correlation coefficients were about 0.5-1.0, demonstrating good 
reproducibility between the biological replicates in each experimental group: Tg-ctrl and 
WT-ctrl (Fig. 1A-C), as well as Tg-TRF and Tg-PO (Fig. 1D-F). Principal component 
analysis also showed that the biological replicates in each group were closely clustered, 
as visualized by the separation trends between Tg-ctrl and WT-ctrl (Fig. 2A-C), and also 
between Tg-TRF and Tg-PO (Fig. 2D-F).  
To investigate alterations in the proteome profile of AβPP/PS1 mice brains, a 
comparison was made between the Tg-ctrl versus WT-ctrl groups (Table 1, 
Supplementary Table 3). A total of 155 proteins were significantly altered (p < 0.05) in 
Tg-ctrl compared with WT-ctrl mice hippocampus, mPFC, and striatum. Analyses of 
proteome data in these mice groups showed that the levels of 43 proteins were altered (p 
< 0.05) in the hippocampus (26 upregulated and 17 downregulated). The levels of 99 
proteins were altered (p < 0.05) in mPFC (16 upregulated and 83 downregulated). In the 
striatum, the levels of 13 proteins were altered (p < 0.05), with 12 of them upregulated 
and 1 downregulated.  
Next, we compared the protein levels in Tg-TRF and Tg-PO groups to test the 
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effect of TRF on the AβPP/PS1 mice brain proteome (Table 1, Supplementary Table 4). 
We found that the levels of 255 proteins were significantly altered (p < 0.05) in Tg-TRF 
compared to Tg-PO mice in all brain regions studied. Of these, 203 proteins levels were 
altered (p < 0.05) in the hippocampus (65 upregulated and 138 downregulated). In the 
mPFC, a total of 29 proteins levels were altered (p < 0.05) with 14 upregulated and 15 
downregulated proteins. The levels of 23 proteins were altered (p < 0.05) in the striatum 
of Tg-TRF group compared with Tg-PO with 18 and 5 proteins being upregulated or 
downregulated, respectively.  
Pairwise comparison of the differentially expressed proteins (p < 0.05) between 
Tg-ctrl versus WT-ctrl and Tg-TRF versus Tg-PO was made to investigate the overlapped 
proteins between these groups for each brain region (Fig. 3). In the hippocampus, two 
proteins (0.8%) overlapped between Tg-ctrl versus WT-ctrl and Tg-TRF versus Tg-PO 
groups: amyloid beta A4 protein (APP) and receptor-type tyrosine-protein phosphatase 
alpha (PTPRA). There was no overlap in mPFC and striatum. APP and PTPRA proteins 
were significantly increased (p < 0.05) in Tg-ctrl group compared with WT-ctrl (Fig. 3). 
In contrast, these proteins were significantly decreased (p < 0.05) in Tg-TRF group 
compared with Tg-PO (Fig. 3).  
 
Pathway analysis 
Pathway analysis based on the KEGG reference pathway databases 
(http://www.genome.jp/kegg/pathway.html) revealed that most of the significantly 
altered proteins between Tg-ctrl versus WT-ctrl mice hippocampus (Table 2) were 
involved in Alzheimer’s disease, oxidative phosphorylation, glutamatergic, cholinergic, 
and serotonergic synapse pathways. In medial prefrontal cortex (Table 2), the altered 
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proteins between Tg-ctrl versus WT-ctrl participated in metabolic pathways, Parkinson’s 
disease, ribosome, Alzheimer’s disease, and biosynthesis of amino acids. Meanwhile, in 
the striatum (Table 2), the altered proteins between Tg-ctrl versus WT-ctrl groups were 
engaged in metabolic pathways, Alzheimer’s disease, oxidative phosphorylation, 
Parkinson’s disease, and Huntington’s disease.    
Pathway analysis of the altered proteins between Tg-TRF versus Tg-PO mice 
hippocampus (Table 3) showed that TRF modulated proteins were involved in metabolic 
pathways, Huntington’s disease, Alzheimer’s disease, oxidative phosphorylation, and 
Parkinson’s disease. In the medial prefrontal cortex (Table 3), the altered proteins 
between Tg-TRF and Tg-PO were engaged in metabolic pathways, biosynthesis of amino 
acids, carbon metabolism, Alzheimer’s disease, and arginine and proline metabolism. 
Most of the significantly altered proteins between Tg-TRF and Tg-PO in the striatum 
(Table 3) participated in glycerolipid metabolism, glycolysis/gluconeogenesis, 




The aim of the present study was to assess the effect of natural-source antioxidant 
treatment with tocotrienol-rich fraction (TRF) on the proteome profiles of AβPP/PS1 
mice brains, by analyzing hippocampus, mPFC, and striatum. These regions were 
selected to represent areas of the brain known to be severely affected (hippocampus and 
mPFC) and moderately affected (striatum) in AD. According to the amyloid cascade 
hypothesis, abnormal aggregation of Aβ, including the formation of soluble oligomers 
and insoluble fibrils, leading to the formation of senile plaques, is an initial pathological 
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alteration that leads to AD [31]. Previous studies have suggested that modulating Aβ 
aggregation and reducing brain Aβ aggregates would be beneficial as therapeutic targets 
against AD [32,33]. However, amyloid burden and cognitive decline poorly correlate.  
There have been failures of recent clinical trials aimed at preventing cognitive decline by 
removing amyloid burden [34–36]. Proteomics studies still have a place for unravelling 
molecular mechanisms contributing to AD pathogenesis, and possibly finding new 
therapeutic strategies to combat the disease.  
In this study, by comparing the proteome profiles of AβPP/PS1 mice (Tg-ctrl) 
with wild type (WT-ctrl) mice, we demonstrated alterations in levels of 43, 99, and 13 
proteins in the AβPP/PS1 mice hippocampus, mPFC, and striatum, respectively (Table 1; 
Supplementary Table 3). Comparisons between the AβPP/PS1 mice that received TRF 
(Tg-TRF) with the vehicle control group that received palm oil stripped of vitamin E (Tg-
PO) showed 203, 29, and 23 proteins were altered in the hippocampus, mPFC, and 
striatum, separately (Table 1; Supplementary Table 4). The altered proteins in both 
comparisons were visualized in a Venn diagram to identify the overlapping proteins 
between groups in each studied brain region. We found that only two proteins: amyloid 
beta A4 protein (alternative name: amyloid precursor protein) (APP) and receptor-type 
tyrosine-protein phosphatase alpha (PTPRA), overlapped between both comparisons and 
showed a higher expression in AβPP/PS1 mice hippocampus compared with the wild-
type mice (Fig. 3). The current study used double transgenic mice APP/PS1dE9, which 
expressed a chimeric mouse/human APP isoform 695 (line C3-3) driven by the mouse 
prion promoter, with a Swedish mutation in the APP sequence, that leads to increased 
total Aβ generation [22,37]. These mice also expressed human PSEN1 lacking of exon 9 
(line S-9), which represented the AD-associated mutation with exon 9 deletion [38]. 
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Therefore, it is expected to find an increased level of APP protein in the AβPP/PS1 mice 
hippocampus. Notably, the expression of these proteins was decreased in the AβPP/PS1 
mice supplemented with TRF (Fig. 3). This finding concurred with our previous study 
which demonstrated that TRF modulated amyloid pathology by inhibiting Aβ fibril and 
oligomer formation in vitro, and also reduced Aβ deposition in AβPP/PS1 mice brain, 
particularly in the hippocampus and cortex [17]. Unfortunately, we can not explain in 
detail how TRF was able to modulate this protein in the current untargeted proteomics 
analysis. Whether TRF is affecting APP levels, or APP metabolism to Aβ, or affecting 
steady-state levels of Aβ warrants further investigation. In our earlier study, we performed 
enzyme-linked immunosorbent assay (ELISA) and found that the levels of both Aβ40 and 
Aβ42 in hippocampus and cortex of AβPP/PS1 mice were not affected by TRF [17]. We 
also conducted metabolomics analysis to understand the possible molecular mechanisms 
underlying this process and found that TRF was able to exhibit its potential therapeutic 
effects by modulating several metabolic pathways such as bioenergetics, 
neurotransmission, membrane lipid metabolism, and oxidative stress defense [18].  
Other than APP protein, PTPRA level was also increased (p < 0.05) in the 
AβPP/PS1 mice hippocampus, and decreased with TRF supplementation (Fig. 3). Several 
studies have reported the importance of PTPRA in learning and memory, and this protein 
has been considered as a key mediator of neuronal migration and synaptic plasticity 
[39,40]. The potential therapeutic target of tyrosine-protein phosphatase in various 
diseases including neuroinflammatory diseases has been reported [41–43]. PTPRA plays 
a central role as an activator of Src family kinases [44]. Src family kinases are a group of 
genes that encode for nonreceptor protein kinases involved in cell growth regulation. c-
Src, a product of Src family kinases is highly expressed in the brain [45]. However, 
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overexpressed or highly activated c-Src causes uncontrolled cell proliferation, leading to 
various cancers in human [46,47]. In addition, c-Src activation has also considered a key 
contributor to glutamate-induced neurodegeneration [48]. Thus, TRF may exert its 
neuroprotective effect by reducing the increased level of PTPRA in AβPP/PS1 mice 
hippocampus. Even though the exact mechanism is currently unclear,  a previous study 
has demonstrated the neuroprotective mechanism of tocotrienol by suppressing 
glutamate-induced early activation of the c-Src kinase at nanomolar concentrations, 
thereby, preventing neuronal cell death [49]. Consistent with this, it was found in another 
study that tocotrienol inhibited the activation of c-Src and extracellular signal-regulated 
protein kinase (ERK) in the mitogen-activated protein kinase (MAPK) cell signaling 
pathway for neuronal death, resulting in improved cognitive impairment in aged rats [50].  
Aβ may not be the only player driving the cognitive decline in AD. Microtubule 
associated protein tau (MAPT) has also been considered a contributor to the onset of AD, 
leading to neuropathological conditions such as selective neuronal death, synaptic loss, 
and deposition of abnormal proteins including Aβ plaques and neurofibrillary tangles 
(NFTs). MAPT was identified in these mice brains in the present study, yet the expression 
of this protein was unchanged. The AβPP/PS1 mouse is a transgenic mouse model that 
only develops amyloid deposits.  It is a model system and fails to meet all criteria of AD 
human neuropathology such as formation of phosphorylated tau enriched NFTs [51,52]. 
In order to understand the effect of TRF on both amyloid and tau pathologies in the mouse 
brain, a further study is necessary by using different mouse models such as triple 
transgenic mouse (3xTgAD) which carries APP, PSEN, and MAPT mutations [53]. 
Neuroinflammation, an innate immunological response of the nervous system is 
also considered a hallmark of neurodegenerative diseases [54]. Microglia and astrocytes 
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are the major types of glial cells and predominant mediators of inflammation within the 
central nervous system (CNS). The microglial function is regulated by apolipoprotein E 
(APOE) amongst other factors. APOE protein level was not significantly different in the 
AβPP/PS1 mice control compared to wild type mice (Supplementary Table 1). 
Furthermore, microglial activation and the release of inflammatory mediators such as 
nitric oxide, chemokines, interleukins, and cytokines are also among the pathological 
mechanisms underlying the progression of neurodegenerative diseases [55,56]. In this 
study, we found increased glial fibrillary acidic protein (GFAP) and decreased interleukin 
enhancer-binding protein 2 (ILF2) levels in the AβPP/PS1 mice hippocampus 
(Supplementary Table 3). TRF supplementation was, however, unable to modulate these 
proteins. This finding was in line with our previous study using an immunohistochemistry 
approach, which reported that AβPP/PS1 mice exhibited higher Iba1-immunoreactivity 
in the hippocampus and cortex compared with wild type mice, but no difference was 
observed in the TRF treated group [17]. It seems that TRF supplementation on these mice 
has no effect on microglial activity.  
Recently, proteome profiling in human AD brain has reported AD-related 
alterations in the expression of over 5000 proteins across six different brain regions [57]. 
The study also highlighted four candidate genes, syntaxin binding protein 1 (STXBP1), 
collapsin response-mediator protein 1 (CRMP1), actin-related protein 10 homologue 
(ACTR10), and amphiphysin (AMPH), which might be key mediators of the protein 
expression response to AD [57]. STXBP1, CRMP1, and AMPH proteins were identified 
in all selected brain regions of mice used in our study, but were not significantly altered 
(Supplementary Table 1 and 2). However, ACTR10 protein level was significantly 
decreased in the AβPP/PS1 mice hippocampus treated with TRF compared with Tg-PO 
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group, which may be a positive effect (Supplementary Table 4). ACTR10 plays a central 
role in the prion propagation and clearance process, thereby, affecting prion susceptibility 
[58]. This protein has also been identified in the aging mouse hippocampus [59] and AD 
human brain [57].  
Genome-wide association studies (GWAS) have reported a number of genes 
related to AD, including clusterin (CLU), ephrin type-A receptor 1 (EPHA1), 
phosphatidylinositol-binding clathrin assembly protein (PICALM), myc box-dependent-
interacting protein 1 (BIN1), ATP binding cassette subfamily A member 7 (ABCA7), 
membrane-spanning 4-domains subfamily A (MS4A), complement receptor type 1 (CR1), 
myeloid cell surface antigen CD33 (CD33), and CD2-associated protein (CD2AP) [60–
62]. We identified three proteins with these gene names from our analysis (CLU, 
PICALM, and BIN1), but these proteins were not significantly altered in any of the mice 
groups. We found decreased expression of ephrin type-A receptor 4 (EPHA4) in Tg-TRF 
group, which could be neuroprotective. This is supported by a previous study which 
demonstrated EPHA4 as a mediator for synaptic plasticity impairment induced by Aβ, 
and the blockade of EPHA4 activity through targeting its ligand-binding domain reversed 
the synaptic deficits in AβPP/PS1 mice [63]. 
Aβ accumulation is considered a key early event in AD pathophysiology. 
However, several pathophysiological events may occur earlier than Aβ peptides in AD 
pathogenesis, including alterations in oxidative stress, nitrosative stress, metabolic, 
mitochondria, and inflammatory [64–68]. Thus, supplementation with a natural 
antioxidant (i.e. vitamin E) could be essential to protect the brain against these events. 
Vitamin E plays a central role in scavenging peroxyl radical, preventing lipid peroxidation, 
and protecting polyunsaturated fatty acids (PUFAs) and other cell membranes 
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components and lipoproteins from oxidation by free radicals [69]. Tocotrienols in 
particular have been shown previously to exert antioxidative effect in in vitro and in vivo 
studies [70–72]. For instance, up to 100 µmol/L of γ-tocotrienol concentration protected 
against hydrogen peroxide (H2O2)-induced cell death and apoptosis in primary astrocyte 
cultures [70]. In addition, α-tocotrienol has been shown to protect neuronal cell from 
glutamate-induced toxicity primarily by a direct antioxidant action [71]. In an in vivo 
study, three months supplementation of TRF (200 mg/kg) has been reported to markedly 
reduce lipid peroxidation, modulate antioxidant enzymes activity and brain arginine 
metabolism, and also improve memory in aged rats [19,72]. Tocotrienols 
supplementation has also been reported to improve lipid profiles in chronic hemodialysis 
patients [73]. In line with the previous findings, we also observed possible antioxidative 
mechanism of TRF in AβPP/PS1 mice brain, particularly hippocampus. The present study 
demonstrated decreased (p < 0.05) expression of proteins involved in oxidative 
phosphorylation such as inorganic pyrophosphatase (PPA1) and cytochrome c1 (CYC1) 
in the AβPP/PS1 mice hippocampus (Table 2). In contrast, six proteins involved in this 
pathway (Table 3) were increased (p < 0.05) with TRF supplementation in these mice 
hippocampus: NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 10 
(NDUFB10), NADH dehydrogenase [ubiquinone] iron-sulfur protein 2 (NDUFS2), 
NADH dehydrogenase [ubiquinone] flavoprotein 1 (NDUFV1), NADH dehydrogenase 
[ubiquinone] 1 alpha subcomplex subunit 12 (NDUFA12), ATP synthase subunit beta 
(ATP5B), and V-type proton ATPase subunit B, brain isoform (ATP6V1B2). Oxidative 
stress and mitochondrial dysfunction have been recognized as among the most prominent 
features implicated in AD pathophysiology [74]. Previous studies have shown a 
correlation between the decreased expression of nuclear or mitochondrial genes in the 
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neocortex of AD patients with progressive reductions in brain glucose metabolism [75,76]. 
Deregulation of oxidative phosphorylation proteins was also observed in a triple 
transgenic mouse of AD [77]. Thus, the modulations of proteins expression involved in 
this pathway may be due to an antioxidative mechanism of TRF reducing oxidative stress 
in the AβPP/PS1 mice brain.  
Overall, the present study provides insights into understanding the proteome 
changes in the hippocampus, mPFC, and striatum of AβPP/PS1 transgenic mice 
supplemented with TRF. Our proteomics analysis using liquid chromatography coupled 
to Q Exactive HF Orbitrap mass spectrometry demonstrated that the modulation of 
proteome profile by TRF could be due to its effect on Aβ, or independent of this, as 
illustrated in Figure 4. For instance, the decreased levels of APP in the AβPP/PS1 mice 
receiving TRF may be key to the reduced Aβ deposits and improved cognitive function 
[17]. In addition, the reduced level of PTPRA is possibly involved in the decreased 
activation of c-Src kinase, preventing glutamate-induced neurodegeneration and also 
contributes to the improved memory in the AβPP/PS1 mice. The mechanism of TRF in 
improving cognitive function may also possibly occur by modulating other proteins in 
metabolic pathways, Alzheimer’s disease, and oxidative phosphorylation. Altered 
metabolic pathways related to bioenergetics, neurotransmission, membrane lipid 
metabolism, and oxidative stress defense as reported in our previous metabolomics 
analysis may also lead to the improved memory in AβPP/PS1 mice [18] (Figure 4).     
Even though our proposed mechanism of TRF as illustrated in Figure 4 is 
speculative at this moment, hopefully it can at least provide a general overview to 
understand the possible molecular mechanisms of TRF in ameliorating the cognitive 
deficits in AβPP/PS1 mice. In future, further studies such as multi-omics integration 
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approach or targeted proteomics and metabolomics can be implemented to understand the 
relationship between metabolites and proteins changes, and the exact molecular 
mechanisms for TRF to slow down AD progression. In addition, a study using AβPP/PS1 
mice may open avenues to understand the mechanism of TRF in modulating amyloid 
pathology, but it is important to note that this animal model does not represent overall 
AD pathogenesis. Thus, the use of other transgenic mouse models such as triple 
transgenic mouse which carries APP, PSEN, and MAPT mutations, or 5xFAD mouse 
may be useful to confirm and enhance our understanding of AD pathogenesis. 
In summary, TRF potentially exerts its neuroprotective effects in AβPP/PS1 mice 
brain by modulating proteins involved in various biochemical pathways including 
metabolic pathways, Alzheimer’s disease, and oxidative phosphorylation. Our current 
findings demonstrated that TRF supplementation altered proteins in the AβPP/PS1 mice 
brain in a region-specific manner. TRF also modulated APP and PTPRA protein 
expression in AβPP/PS1 mice hippocampus. However, whether the improved cognitive 
performance upon TRF treatment is associated with the changes in APP and PTPRA 
levels warrants further investigation. 
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Figure 1: Multi-scatter plots with Pearson correlation values of 0.5-1.0 suggest a good 
correlation between data obtained from the different experimental groups and biological 
replicates in the AβPP/PS1 mice without supplementation (Tg-ctrl) and wild-type mice 
(WT-ctrl) in the (A) hippocampus, (B) medial prefrontal cortex, and (C) striatum, as well 
as in the AβPP/PS1 mice received tocotrienol-rich fraction (Tg-TRF) and AβPP/PS1 mice 
received palm oil stripped of vitamin E (Tg-PO) groups in the (D) hippocampus, (E) 
medial prefrontal cortex, and (F) striatum. 
 
Figure 2: Principal component analysis (PCA) plots of the proteomics data reveals 
replicates for each of the experimental group are closely clustered, suggesting high 
consistency between replicates in the AβPP/PS1 mice without supplementation (Tg-ctrl) 
and wild-type mice (WT-ctrl) in the (A) hippocampus, (B) medial prefrontal cortex, and 
(C) striatum, as well as in the AβPP/PS1 mice received tocotrienol-rich fraction (Tg-TRF) 
and AβPP/PS1 mice received palm oil stripped of vitamin E (Tg-PO) groups in the (D) 
hippocampus, (E) medial prefrontal cortex, and (F) striatum.  
 
Figure 3: Venn diagram for differentially expressed proteins between groups in 
AβPP/PS1 mice without supplementation (Tg-ctrl) versus wild-type mice (WT-ctrl) and 
AβPP/PS1 mice received tocotrienol-rich fraction (Tg-TRF) versus AβPP/PS1 mice 
received palm oil stripped of vitamin E (Tg-PO) groups in hippocampus, medial 
prefrontal cortex, and striatum. The overlapped proteins between the groups were listed 




Figure 4: Proposed mechanisms of TRF action in improving cognitive function in 
AβPP/PS1 mice. Aβ deposits, altered metabolites, and proteins expression cause neuronal 
dysfunction leading to cognitive impairment. (A) TRF reduces Aβ deposition and 
improves cognitive function (black arrow) (Ibrahim et al. 2017); (B) TRF modulates 
metabolic pathways, reducing neuronal dysfunction, and improves cognitive function 
(blue arrow) (Durani et al.2018); (C) TRF modulates amyloid beta A4 protein (APP) 
leading to reduced Aβ deposits and improved cognitive function. TRF also modulates 
receptor-type tyrosine-protein phosphatase alpha (PTPRA), reducing neuronal 
dysfunction, and improves memory. TRF may also improve memory by modulating other 
proteins involved in metabolic pathways, Alzheimer’s disease pathway, and oxidative 
phosphorylation (purple arrow). Figure modified from Durani et al. [18]. 
 
 
 
 
